A Study on the Efficacy and Gut Microbiota of Berberine and Probiotics in Patients With Newly Diagnosed Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.
Also called NCT02861261
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 400 participants
- Registry
-
NCT02861261
-
- Other papers using this trial's data
- Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02861261. Randomized; double masking; primary purpose treatment. Start 2016-08-18 (actual); primary completion 2017-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study on the Efficacy and Gut Microbiota of Berberine and Probiotics in Patients With Newly Diagnosed Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- 1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder
- Intervention (Drug)
- 1. Berberine placebo tablets ; 2. ProMetS probiotics powder
- Intervention (Drug)
- 1. Berberine hydrochloride tablets; 2. Probiotics placebo powder
- Intervention (Drug)
- 1. Berberine placebo tablets; 2. Probiotics placebo powder
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
Record details
- Record id
cardio:ct-nct02861261- Content hash
96c7c3cef309b7248f625d5d876147868a664bfc1ee5847bb83e48c8ad1ab8c0